The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II/III trial of conventional paclitaxel and carboplatin (cTC) versus dose-dense paclitaxel and carboplatin (ddTC), with or without bevacizumab (Bmab), for stage IVb, recurrent, or persistent cervical cancer (CC): Japan Clinical Oncology Group study (JCOG1311).
 
Ryo Kitagawa
Honoraria - Eisai
 
Mitsuya Ishikawa
No Relationships to Disclose
 
Taro Shibata
No Relationships to Disclose
 
Kenichi Miyamoto
No Relationships to Disclose
 
Hiroaki Kobayashi
No Relationships to Disclose
 
Takashi ONDA
Honoraria - Chugai Pharma; Ono Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kaken Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Munetaka Takekuma
No Relationships to Disclose
 
Fumiaki Takahashi
No Relationships to Disclose
 
Harushige Yokota
No Relationships to Disclose
 
Michihiro Tanikawa
No Relationships to Disclose
 
Mika Mizuno
No Relationships to Disclose
 
Tetsuro Oishi
No Relationships to Disclose
 
Yoichi Aoki
No Relationships to Disclose
 
Shin Nishio
No Relationships to Disclose
 
Takashi Iwata
No Relationships to Disclose
 
Nobuo Yaegashi
No Relationships to Disclose